<DOC>
	<DOC>NCT00635700</DOC>
	<brief_summary>This study aims to determine whether ziprasidone is superior to placebo over 24 weeks for patients with the psychosis prodrome.</brief_summary>
	<brief_title>Ziprasidone in the Psychosis Prodrome</brief_title>
	<detailed_description />
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<criteria>SIPS criteria for psychosis prodrome clinically referred prolonged QTc history of syncope</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>psychosis</keyword>
	<keyword>schizophrenia</keyword>
	<keyword>prodrome</keyword>
	<keyword>ziprasidone</keyword>
	<keyword>placebo</keyword>
</DOC>